Radioembolization with holmium-containing microspheres: Use of the Holmium Platform for the treatment of patients with hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032073

Enrollment

Registered

2023-06-13

Start date

2022-06-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: Patients with hepatocellulary carcinoma (HCC) who underwent radioembolization planning and treatment with QuiremScout, Q-Suite and QuiremSpheres (Terumo, The Netherlands)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Radioembolization treatment using the Holmium Platform (QuiremScout, Q-Suite, QuiremSpheres)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival (end of follow-up 12 months after enrollment of the final patient)	—

Secondary

Measure	Time frame
progression free survival (liver-related, overall)	—

Countries

Germany

Contacts

Public ContactRobert Drescher

Universitätsklinikum Jena, Klinik für Nuklearmedizin

robert.drescher@med.uni-jena.de+4936419329801

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026